Endoscopic surveillance after colonic polyps and colorrectal cancer resection. 2018 update
Mangas-Sanjuan C 1, Jover R 2, Cubiella J 3, Marzo-Castillejo M 4, Balaguer F 5, Bessa X 6, Bujanda L 7, Bustamante M 8, Castells A 5, Diaz-Tasende J 9, Díez-Redondo P 10, Herráiz M (11), Mascort-Roca JJ (12), Pellisé M (5), Quintero E (13); Grupo de Cribado del Cáncer Colorrectal de la Sociedad Española de Epidemiología.
There is limited scientific evidence available to stratify the risk of developing metachronous colorectal cancer after resection of colonic polyps and to determine surveillance intervals and is mostly based on observational studies.
However, while awaiting further evidence, the criteria of endoscopic follow-up needs to be unified in our setting. Therefore, the Spanish Association of Gastroenterology, the Spanish Society of Family and Community Medicine, the Spanish Society of Digestive Endoscopy, and the Colorectal Cancer Screening Group of the Spanish Society of Epidemiology, have written this consensus document, which is included in chapter 10 of the "Clinical Practice Guideline for Diagnosis and Prevention of Colorectal Cancer. 2018 Update". Important developments will also be presented as regards the previous edition published in 2009.
First of all, situations that require and do not require endoscopic surveillance are established, and the need of endoscopic surveillance of individuals who do not present a special risk of metachronous colon cancer is eliminated. Secondly, endoscopic surveillance recommendations are established in individuals with serrated polyps.
Finally, unlike the previous edition, endoscopic surveillance recommendations are given in patients operated on for colorectal cancer. At the same time, it represents an advance on the European guideline for quality assurance in colorectal cancer screening, since it eliminates the division between intermediate risk group and high risk group, which means the elimination of a considerable proportion of colonoscopies of early surveillance.
Finally, clear recommendations are given on the absence of need for follow-up in the low risk group, for which the European guidelines maintained some ambiguity.